Sensorium Therapeutics Inc. has reported that the U.S. FDA has cleared the IND application for SNTX-2643 (SENS-01), its lead anxiety program. First-in-human dosing begins in Q3 2025.
Acurex Biosciences Corp. has divulged fused quinone compounds acting as ferroptosis inhibitors reported to be useful for the treatment of mitochondrial disease.
Design Therapeutics Inc. has described transcription modulators reported to be useful for the treatment of myotonic dystrophy type 1 (DM1) and Fuchs’ dystrophy.
Merck Sharp & Dohme LLC has identified NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), neuroinflammation, inflammatory skin, inflammatory joint and autoimmune diseases, Alzheimer’s disease and Parkinson’s disease, among others.
Vanderbilt University has synthesized muscarinic M4 receptor positive allosteric modulators (PAMs) reported to be useful for the treatment of Alzheimer’s disease, pain, schizophrenia and sleep disorders.
The oxidase, cytochrome c, assembly 1-like (OXA1L) gene plays a key role in inserting and assembling proteins in the inner mitochondrial membrane, and recent studies have linked some variants to mitochondrial encephalopathy. However, the exact disease mechanism and causal link remain unclear.
Researchers at Washington University reported the preclinical validation of [18F]FQ-NeuroROS, a redox-sensitive reporter probe for imaging neuroinflammation in preclinical models of multiple sclerosis (MS). MS is a chronic autoimmune disorder of the central nervous system (CNS), characterized by inflammatory cell infiltration, demyelination and axonal damage.
RSS
